AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
vorasidenib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| isocitrate dehydrogenase inhibitors | 5829 | 1644545-52-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Vorasidenib is a small molecule inhibitor that targets isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2) enzymes. In vitro, vorasidenib inhibited the IDH1 wild type and mutant variants, including R132H and the IDH2 wild type and mutant variants. In cell-based and in vivo tumor models expressing IDH1 or IDH2 mutated proteins, vorasidenib decreased production of 2-hydroxyglutarate (2-HG) and partially restored cellular differentiation.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 6, 2024 | FDA | Servier | |
| Sept. 17, 2025 | EMA | Les Laboratoires Servier | |
| Sept. 19, 2025 | PMDA | Nihon Servier Co., Ltd. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01XM04 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Isocitrate dehydrogenase (IDH) inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| FDA MoA | N0000190118 | Cytochrome P450 3A Inducers |
| FDA MoA | N0000193614 | Isocitrate Dehydrogenase 2 Inhibitors |
| FDA EPC | N0000193615 | Isocitrate Dehydrogenase 2 Inhibitor |
| FDA EPC | N0000193987 | Isocitrate Dehydrogenase 1 Inhibitor |
| FDA MoA | N0000193988 | Isocitrate Dehydrogenase 1 Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Related Drugs by ATC class:
L01XM Isocitrate dehydrogenase (IDH) inhibitors 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Grade 2 astrocytoma | indication | 55353007 | DOID:3078 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 10MG | VORANIGO | SERVIER | N218784 | Aug. 6, 2024 | RX | TABLET | ORAL | 12433895 | July 11, 2034 | A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION FOLLOWING SURGERY, WHEREIN THE CANCER IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA |
| 40MG | VORANIGO | SERVIER | N218784 | Aug. 6, 2024 | RX | TABLET | ORAL | 12433895 | July 11, 2034 | A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION FOLLOWING SURGERY, WHEREIN THE CANCER IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA |
| 10MG | VORANIGO | SERVIER | N218784 | Aug. 6, 2024 | RX | TABLET | ORAL | 11844758 | Dec. 4, 2035 | A METHOD OF TREATING A GLIOMA CHARACTERIZED BY AN IDHI MUTATION FOLLOWING SURGERY, WHEREIN THE GLIOMA IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA |
| 40MG | VORANIGO | SERVIER | N218784 | Aug. 6, 2024 | RX | TABLET | ORAL | 11844758 | Dec. 4, 2035 | A METHOD OF TREATING A GLIOMA CHARACTERIZED BY AN IDHI MUTATION FOLLOWING SURGERY, WHEREIN THE GLIOMA IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA |
| 10MG | VORANIGO | SERVIER | N218784 | Aug. 6, 2024 | RX | TABLET | ORAL | 11345677 | Jan. 16, 2039 | A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 OR IDH2 MUTATION OR COMBINATION THEREOF FOLLOWING SURGERY, WHEREIN THE CANCER IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA |
| 40MG | VORANIGO | SERVIER | N218784 | Aug. 6, 2024 | RX | TABLET | ORAL | 11345677 | Jan. 16, 2039 | A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 OR IDH2 MUTATION OR COMBINATION THEREOF FOLLOWING SURGERY, WHEREIN THE CANCER IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 10MG | VORANIGO | SERVIER | N218784 | Aug. 6, 2024 | RX | TABLET | ORAL | Aug. 6, 2029 | NEW CHEMICAL ENTITY |
| 40MG | VORANIGO | SERVIER | N218784 | Aug. 6, 2024 | RX | TABLET | ORAL | Aug. 6, 2029 | NEW CHEMICAL ENTITY |
| 10MG | VORANIGO | SERVIER | N218784 | Aug. 6, 2024 | RX | TABLET | ORAL | Aug. 6, 2031 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) OR ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION FOLLOWING SURGERY INCLUDING BIOPSY, SUB-TOTAL RESECTION, OR GROSS TOTAL RESECTION |
| 40MG | VORANIGO | SERVIER | N218784 | Aug. 6, 2024 | RX | TABLET | ORAL | Aug. 6, 2031 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) OR ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION FOLLOWING SURGERY INCLUDING BIOPSY, SUB-TOTAL RESECTION, OR GROSS TOTAL RESECTION |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Isocitrate dehydrogenase [NADP], mitochondrial | Enzyme | INHIBITOR | IC50 | 6.95 | DRUG LABEL | DRUG LABEL | |||
| Isocitrate dehydrogenase [NADP] cytoplasmic | Enzyme | INHIBITOR | IC50 | 7.69 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| CHEMBL4279047 | ChEMBL_ID |
| C000716758 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB17097 | DRUGBANK_ID |
| 4043316 | VANDF |
| C4726974 | UMLSCUI |
| CHEBI:756658 | CHEBI |
| 9UO | PDB_CHEM_ID |
| CHEMBL4594378 | ChEMBL_ID |
| 10525 | INN_ID |
| 117817422 | PUBCHEM_CID |
| 388277 | MMSL |
| 43035 | MMSL |
| d10209 | MMSL |
| 10663 | IUPHAR_LIGAND_ID |
| 789Q85GA8P | UNII |
| 2690647 | RXNORM |
| 933316181000036101 | SNOMEDCT_US |
| D11834 | KEGG_DRUG |
| 019823 | NDDF |
| 019825 | NDDF |
| 789Q85GA8P | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| VORANIGO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72694-728 | TABLET, FILM COATED | 40 mg | ORAL | NDA | 31 sections |
| VORANIGO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72694-879 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 31 sections |